Literature DB >> 15946122

Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death.

Cristina d'Abramo1, Sara Massone, Jean-Marc Zingg, Antonio Pizzuti, Philippe Marambaud, Bruno Dalla Piccola, Angelo Azzi, Umberto M Marinari, Maria A Pronzato, Roberta Ricciarelli.   

Abstract

Recent data indicate that PPARgamma (peroxisome proliferator-activated receptor gamma) could be involved in the modulation of the amyloid cascade causing Alzheimer's disease. In the present study we show that PPARgamma overexpression in cultured cells dramatically reduced Abeta (amyloid-beta) secretion, affecting the expression of the APP (Abeta precursor protein) at a post-transcriptional level. APP down-regulation did not involve the pathway of the secretases and correlated with a significant induction of APP ubiquitination. Additionally, we demonstrate that PPARgamma was able to protect the cells from H(2)O(2)-induced necrosis by decreasing Abeta secretion. Taken together, our results indicate a novel mechanism at the basis of the neuroprotection shown by PPARgamma agonists and an additional pathogenic role for Abeta accumulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15946122      PMCID: PMC1276971          DOI: 10.1042/BJ20050560

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  27 in total

1.  A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity.

Authors:  S Weggen; J L Eriksen; P Das; S A Sagi; R Wang; C U Pietrzik; K A Findlay; T E Smith; M P Murphy; T Bulter; D E Kang; N Marquez-Sterling; T E Golde; E H Koo
Journal:  Nature       Date:  2001-11-08       Impact factor: 49.962

2.  Assessment of proteasome activity in cell lysates and tissue homogenates using peptide substrates.

Authors:  Kenneth J Rodgers; Roger T Dean
Journal:  Int J Biochem Cell Biol       Date:  2003-05       Impact factor: 5.085

3.  Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice.

Authors:  G P Lim; F Yang; T Chu; E Gahtan; O Ubeda; W Beech; J B Overmier; K Hsiao-Ashec; S A Frautschy; G M Cole
Journal:  Neurobiol Aging       Date:  2001 Nov-Dec       Impact factor: 4.673

4.  Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease.

Authors:  G P Lim; F Yang; T Chu; P Chen; W Beech; B Teter; T Tran; O Ubeda; K H Ashe; S A Frautschy; G M Cole
Journal:  J Neurosci       Date:  2000-08-01       Impact factor: 6.167

Review 5.  Role of the proteasome in Alzheimer's disease.

Authors:  F Checler; C A da Costa; K Ancolio; N Chevallier; E Lopez-Perez; P Marambaud
Journal:  Biochim Biophys Acta       Date:  2000-07-26

6.  Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells.

Authors:  Chunhua Qin; Robert Burghardt; Roger Smith; Mark Wormke; Jessica Stewart; Stephen Safe
Journal:  Cancer Res       Date:  2003-03-01       Impact factor: 12.701

7.  NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo.

Authors:  Jason L Eriksen; Sarah A Sagi; Tawnya E Smith; Sascha Weggen; Pritam Das; D C McLendon; Victor V Ozols; Kevin W Jessing; Kenton H Zavitz; Edward H Koo; Todd E Golde
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

8.  Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase.

Authors:  Magdalena Sastre; Ilse Dewachter; Gary E Landreth; Timothy M Willson; Thomas Klockgether; Fred van Leuven; Michael T Heneka
Journal:  J Neurosci       Date:  2003-10-29       Impact factor: 6.167

9.  Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity.

Authors:  Sascha Weggen; Jason L Eriksen; Sarah A Sagi; Claus U Pietrzik; Victor Ozols; Abdul Fauq; Todd E Golde; Edward H Koo
Journal:  J Biol Chem       Date:  2003-06-12       Impact factor: 5.157

10.  The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production.

Authors:  Sarah A Sagi; Sascha Weggen; Jason Eriksen; Todd E Golde; Edward H Koo
Journal:  J Biol Chem       Date:  2003-06-12       Impact factor: 5.157

View more
  27 in total

1.  MH84: A Novel γ-Secretase Modulator/PPARγ Agonist--Improves Mitochondrial Dysfunction in a Cellular Model of Alzheimer's Disease.

Authors:  Maximilian Pohland; Stephanie Hagl; Maren Pellowska; Mario Wurglics; Manfred Schubert-Zsilavecz; Gunter P Eckert
Journal:  Neurochem Res       Date:  2015-12-31       Impact factor: 3.996

2.  Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology.

Authors:  Luis Escribano; Ana-María Simón; Esther Gimeno; Mar Cuadrado-Tejedor; Rakel López de Maturana; Ana García-Osta; Ana Ricobaraza; Alberto Pérez-Mediavilla; Joaquín Del Río; Diana Frechilla
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

3.  Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases.

Authors:  Nicolas G Bazan; Miguel F Molina; William C Gordon
Journal:  Annu Rev Nutr       Date:  2011-08-21       Impact factor: 11.848

4.  Peroxisome proliferator-activated receptor gamma activation inhibits progesterone-stimulated human MUC1 expression.

Authors:  Peng Wang; Neeraja Dharmaraj; Melissa J Brayman; Daniel D Carson
Journal:  Mol Endocrinol       Date:  2010-05-19

5.  Gene- Gene Interaction between PPARG and APOE Gene on Late-Onset Alzheimer's Disease: A Case- Control Study in Chinese Han Population.

Authors:  S Wang; L Guan; D Luo; J Liu; H Lin; X Li; X Liu
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 4.075

Review 6.  Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms.

Authors:  Alexandre Vallée; Yves Lecarpentier; Rémy Guillevin; Jean-Noël Vallée
Journal:  Neuromolecular Med       Date:  2018-03-23       Impact factor: 3.843

7.  Rosiglitazone protects neuroblastoma cells against advanced glycation end products-induced injury.

Authors:  Li Wang; Chun-jiang Yu; Wei Liu; Lu-yang Cheng; Yi-na Zhang
Journal:  Acta Pharmacol Sin       Date:  2011-07-18       Impact factor: 6.150

8.  PPARα activation attenuates amyloid-β-dependent neurodegeneration by modulating Endo G and AIF translocation.

Authors:  Ya-Hsin Cheng; Shih-Wei Lai; Pei-Yi Chen; Jia-Hao Chang; Nai Wen Chang
Journal:  Neurotox Res       Date:  2014-07-22       Impact factor: 3.911

Review 9.  PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.

Authors:  Gary Landreth; Qingguang Jiang; Shweta Mandrekar; Michael Heneka
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

Review 10.  The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications.

Authors:  Qingguang Jiang; Michael Heneka; Gary E Landreth
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.